Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Advanced Solid Tumors · Agitation Associated with Alzheimer’s Disease

Bristol-Myers Squibb Australia

Bristol-Myers Squibb Australia Pty Ltd

Bristol-Myers Squibb Australia clinical programs — 31 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
PO Box 1080, Mount Waverley, Victoria 3149, Australia HQ
6 Employees
TGA registrant Type
Company details
Status
Public
HQ
PO Box 1080, Mount Waverley, Victoria 3149, Australia
Employees
6
Programs
93
Drugs
120
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Bristol-Myers Squibb Australia projects

31 ClinicalTrials.gov programs sponsored by Bristol-Myers Squibb Australia.

Bristol-Myers Squibb Australia has 31 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

31 programs

Clinical programs

  1. BMS-986517

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  2. BMS-986523, BMS-986523

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumor Malignancies

    phase 2 small molecule active

    1 trial

  3. CA001-044

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

  4. CA001-050

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. CA011-023

    Bristol-Myers Squibb Australia Pty Ltd

    DIPSS-Intermediate or High Risk Myelofibrosis

    phase 2 small molecule active

    1 trial

  6. CA027-002

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  7. CA043-001

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC)).

    phase 2 small molecule active

    1 trial

  8. CA0471009

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. CA082-1215

    Bristol-Myers Squibb Australia Pty Ltd

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

  10. CA116-001

    Bristol-Myers Squibb Australia Pty Ltd

    Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    phase 2 small molecule active

    1 trial

  11. CA126-0015

    Bristol-Myers Squibb Australia Pty Ltd

    Oncology, NSCLC and CRC

    phase 2 small molecule active

    1 trial

  12. CA180-226

    Bristol-Myers Squibb Australia Pty Ltd

    Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib

    phase 2 small molecule active

    1 trial

  13. CA204-185

    Bristol-Myers Squibb Australia Pty Ltd

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  14. CA209-032

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or metastatic solid tumors: 1) Triple Negative Breast Cancer (TNBC) 2) Gastric Cancer (GC) 3) Pancreatic Cancer (PC) 4) Small Cell Lung Cancer (SCLC). 5) Bladder Cancer (BC) 6) Ovarian Cancer (OC)

    phase 2 small molecule active

    1 trial

  15. CA209-142

    Bristol-Myers Squibb Australia Pty Ltd

    MSI Negative Colorectal Cancer, MSI Positive Colorectal Cancer

    phase 2 small molecule active

    1 trial

  16. CA209-1533

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  17. CA209-8TT

    Bristol-Myers Squibb Australia Pty Ltd

    Pan tumor

    phase 2 small molecule active

    1 trial

  18. CA224-020

    Bristol-Myers Squibb Australia Pty Ltd

    Neoplasms by site

    phase 2 small molecule active

    1 trial

  19. CA224-048

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  20. CA224-104

    Bristol-Myers Squibb Australia Pty Ltd

    Non small Cell Lung cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. CA224-1044

    Bristol-Myers Squibb Australia Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  22. CA224-106

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced/metastatic hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  23. CA230-1019

    Bristol-Myers Squibb Australia Pty Ltd

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  24. CA2360001

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  25. CA244-0001

    Bristol-Myers Squibb Australia Pty Ltd

    Advance solid tumors

    phase 2 small molecule active

    1 trial

  26. CA258-0001

    Bristol-Myers Squibb Australia Pty Ltd

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  27. CA2660006

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  28. CN008-0003

    Bristol-Myers Squibb Australia Pty Ltd

    Early Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  29. MRTX1719

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  30. Placebo for bms-986435-01

    Bristol-Myers Squibb Australia Pty Ltd

    Heart failure with preserved ejection fraction (HFpEF)

    phase 2 small molecule active

    1 trial

  31. farletuzumab ecteribulin

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Bristol-Myers Squibb Australia have?

31 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.